An Updated Analysis of Pembrolizumab (MK-3475) for Melanoma

June 24, 2014
Jedd D. Wolchok, MD, PhD

Jedd D. Wolchok, MD, PhD, discusses an updated analysis presented at the 2014 ASCO Annual Meeting that looked at pembrolizumab (MK-3475) for patients with melanoma.

Clinical Pearls

Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses an updated analysis presented at the 2014 ASCO Annual Meeting that looked at pembrolizumab (MK-3475) for patients with melanoma. These data were presented by Dr. Antoni Ribas.

  • 72% of patients experienced at least disease control.
  • As of the last data analysis, 88% of patients who had responded were experiencing a continued response.
  • This is characteristic of immunotherapy — the effects of the medicine on the immune system should lead to durable control of the disease.

<<<

Back to "Immunotherapy News from ASCO"